Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.83 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.83 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.83 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.83 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2080798 | 1.00 | MAPK14 (0.83) | MAPK14MAPK12MAPK11MAPK13DDR2 | |
| SCHEMBL2084174 | 0.95 | MAPK14 (0.75) | MAPK14MAPK12MAPK11MAPK13DDR2 | |
| SCHEMBL2084177 | 0.95 | MAPK14 (0.75) | MAPK14MAPK12MAPK11MAPK13DDR2 | |
| SCHEMBL2084054 | 0.93 | MAPK14 (0.80) | MAPK14MAPK12MAPK11MAPK13NTRK1 | |
| SCHEMBL2084050 | 0.93 | MAPK14 (0.80) | MAPK14MAPK12MAPK11MAPK13NTRK1 | |
| SCHEMBL2083249 | 0.92 | MAPK14 (0.80) | MAPK14MAPK12MAPK11MAPK13DDR2 | |
| SCHEMBL2085026 | 0.91 | MAPK14 (0.83) | MAPK14MAPK12MAPK11MAPK13NTRK1 | |
| SCHEMBL2085030 | 0.91 | MAPK14 (0.83) | MAPK14MAPK12MAPK11MAPK13NTRK1 | |
| SCHEMBL22084066 | 0.89 | MAPK14 (0.89) | MAPK14MAPK12MAPK11MAPK13DDR2 | |
| SCHEMBL2083260 | 0.89 | MAPK14 (0.88) | MAPK14MAPK12MAPK11MAPK13NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | MAPK14 128/4885MAPK12 160/4885MAPK11 242/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | MAPK14 100/4885MAPK12 99/4885MAPK11 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.